Diversity in tumor territory of meningioma: Protein expression in vascular endothelial growth factor and epidermal growth factor

  • Parvin Mehdipour Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Firoozeh Javan Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Morteza Faghih-Jouibari Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Mehdi Khaleghi Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Keywords: Vascular Endothelial Growth Factor, Epidermal Growth Factor, Meningioma, Protein Expression, Polymorphism (Genetics), Molecular Evolution

Abstract

Background: Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are involved in tumor development and progression. But, the classified-based data of protein expression (PE) in meningiomas is unavailable. Therefore, we aimed to explore the PE of VEGF and EGF in meningiomas by considering evolutionary strategy and the regional tumor-based assay. Methods: PE was assayed using immunofluorescence (IF) within the peripheral, central, and basal sections of four meningioma tumors, and a lung metastatic brain tumor as a positive control. Results: Diverse characteristics and harmonic cross-talk in the individual sections and between different tumor sections were traced. The mode of PE was puzzling and personalized issue. Co-expression had a key impact on tumor evolution and diverse PE profiles led to draw the heterogenic classification, as the personalized/complementary insight in the functional behavior of VEGF and EGF. D1853N polymorphism of ATM gene was mosaics in two patients with meningiomas. Conclusion: The classified heterogeneity, harmonic co-expression, and diverse functional information in different regions of tumors may lead to predict the aggressiveness mode of tumors as a translational insight to the clinical managements including therapy in brain tumors.

References

1. Schellinger KA, Propp JM, Villano JL, McCarthy BJ. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol 2008; 87(2): 173-9.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97-109.
3. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010; 99(3): 379-91.
4. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131(6): 803-20.
5. Nasser MM, Mehdipour P. Exploration of involved key genes and signaling diversity in brain tumors. Cell Mol Neurobiol 2018; 38(2): 393-419.
6. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458(7239): 719-24.
7. Bitzer M, Opitz H, Popp J, Morgalla M, Gruber A, Heiss E, et al. Angiogenesis and brain oedema in intracranial meningiomas: Influence of vascular endothelial growth factor. Acta Neurochir (Wien) 1998; 140(4): 333-40.
8. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005; 6(2): 209.
9. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313(5998): 144-7.
10. Modjtahedi H, Dean C. The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). Int J Oncol 1994; 4(2): 277-96.
11. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 1984; 44(2): 753-60.
12. Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Mehr Azin M. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene
through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol 2008; 134(11): 1173-80.
13. Mehdipour P, Mahdavi M, Mohammadi-Asl J, Atri M. Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer. Med Oncol 2011; 28(3): 733-7.
14. Mehdipour P, Azarnezhad A. Five- hit hypothesis in ATM gene: An individualized model in a breast cancer patient. Front Biosci (Elite Ed) 2018; 10: 375-83.
15. Karami F, Mehdipour P. Genetic and cellular complexity of brain tumors. In: Mehdipour P, editor. Cancer genetics and psychotherapy. Cham, Switzerland: Springer; 2017. p. 627-65.
16. Mehdipour P. Predisposing, preventive, predictive cancer marker kit (3PCM) (International Application No.: PCT/IB2014/065072) [Patent]. 2006.
17. Estiar MA, Javan F, Zekri A, Mehrazin M, Mehdipour P. Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma. Cancer Biomark 2017; 19(3): 341-51.
18. Jin D, Yu X, Chen B, Li Z, Ding J, Zhao X, et al. Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model. Immunotherapy 2017; 9(7): 537-53.
Published
2019-04-22
How to Cite
1.
Mehdipour P, Javan F, Faghih-Jouibari M, Khaleghi M. Diversity in tumor territory of meningioma: Protein expression in vascular endothelial growth factor and epidermal growth factor. Iran J Neurol. 18(2).
Section
Original Article(s)